BIETTI CRYSTALLINE DYSTROPHY
Clinical trials for BIETTI CRYSTALLINE DYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new BIETTI CRYSTALLINE DYSTROPHY trials appear
Sign up with your email to follow new studies for BIETTI CRYSTALLINE DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy aims to halt blindness from rare crystalline eye disease
Disease control OngoingThis study tests a new treatment called VGR-R01 for people with Bietti Crystalline Dystrophy, a rare inherited eye disease that leads to vision loss. The trial involves 45 adults who will receive the treatment or be in a control group. The main goal is to see if the treatment imp…
Matched conditions: BIETTI CRYSTALLINE DYSTROPHY
Phase: PHASE3 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 10:06 UTC
-
Gene therapy trial aims to halt rare eye disease
Disease control OngoingThis early-stage study tests a new gene therapy called VGR-R01 in 12 adults with Bietti Crystalline Dystrophy, a rare inherited eye disease that causes vision loss. The main goal is to check if the treatment is safe and tolerable. Researchers will monitor for side effects and cha…
Matched conditions: BIETTI CRYSTALLINE DYSTROPHY
Phase: PHASE1 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC